Stockwinners Market Radar for September 14, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:13 EDT MediciNova receives issue notification from U.S. PTC for new MN-166 patent - MediciNova "announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166, ibudilast, for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, wherein the patient expresses unmethylated MGMT, using MN-166 in combination with one or more other therapeutic agents including temozolomide, carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone, and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cover a wide range of doses of MN-166 as well as the other therapeutic agents. The allowed claims also cover different types of glioblastoma including classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma."

18:31 EDT Bentley Systems CEO sells $6.2M in common stock - In a regulatory filing, Bentley Systems disclosed that its CEO Gregory Bentley sold 168.3K shares of common stock on September 12th in a total transaction size of $6.2M.

17:46 EDT Logitech shareholders approve dividend increase of 10% - Logitech "announced that during its annual general meeting the Company's shareholders approved a dividend of approximately CHF 0.96 per share - an increase of approximately 10% compared to FY21 dividend."

17:22 EDT APA Corp. board approves additional buyback of 40M shares of common stock

17:10 EDT Booz Allen CFO Howell to retire, Calderone named next CFO - Booz Allen Hamilton announced that Chief Financial Officer Lloyd W. Howell, Jr. will be retiring December 31, 2022, and Matthew A. Calderone, who currently serves as the firm's Chief Strategy Officer, will succeed him as CFO effective October 1, 2022. Howell will continue in his role of Executive Vice President to assist with the transition in the coming months. "Lloyd has made tremendous contributions to Booz Allen during his 34 year-tenure, culminating most recently in his role as CFO," said Horacio Rozanski, Booz Allen's President and Chief Executive Officer. "Lloyd has helped to guide Booz Allen through a period of tremendous growth and transformation that delivered significant growth in shareholder value and strong returns. He has helped build a world-class financial team and contributed to making Booz Allen the industry growth leader we are today. He leaves our firm well-positioned to scale and grow even faster in the future."

17:01 EDT Granite secures $17M Duncan Creek Diversion Dam contract - Granite "announced that it has been awarded an approximately $17M construction contract by the Placer County Water Agency for updates and improvements at the Duncan Creek Diversion Dam near Foresthill, California. The dam is one of the hundreds of older, small dams in Northern California's Sierra Nevada Mountains. Many of them will require major modifications in the near future in order to bring them up to modern standards. Through the improvement project, the Duncan Creek dam will be brought up to current standards as required by the California Department of Water Resources Division of Safety of Dams, while improving fish passage and allowing for more efficient operation of the facility. The award is anticipated to be included in Granite's third quarter cap."

16:47 EDT J.M. Smucker names Amy Held chief transformation officer - J.M. Smucker announced the formation of a transformation office, which will be overseen by Amy Held in the newly created role of chief transformation officer. Held previously served as the company's chief strategy and international officer. In corresponding decisions, the company announced it will undertake a rigorous search to fill the chief strategy officer role. Held will maintain oversight of strategy while the company recruits to fill the position. Additionally, Tim Wayne, who has taken on the expanded role of VP, international and Away From Home, will now oversee the international business. The company plans to share further details on its transformation office at its upcoming investor day on December 14.

16:36 EDT Newell Brands director Mather sells 50,000 common shares - In a regulatory filing, Newell Brands director Courtney Mather disclosed the sale of 50,000 common shares of the company on September 12 at a price of $18.17 per share.

16:33 EDT Host Hotels recommends shareholders reject MacKenzie Capital mini tender offer - Host Hotels has learned that MacKenzie Capital made an unsolicited "mini-tender" offer for up to 100,000 operating partnership units of Host Hotels & Resorts, L.P. at a price of $13.00 per OP Unit less cash distributions made by Host L.P. after July 15. This follows multiple earlier "mini-tender" offers by the Purchaser launched between 2016 and 2021. Neither the company nor Host L.P. are in any way associated with the MacKenzie Offer, and holders of OP Units are under no obligation to take any action with respect to the MacKenzie Offer. Mini-tender offers seek less than 5% of a company's outstanding equity. This allows the offering company to avoid many of the United States Securities and Exchange Commission disclosure and procedural requirements for tender offers. This guidance advises that mini-tender offers "have been increasingly used to catch investors off guard" and that investors "may end up selling their securities at below-market prices." The company said, "After careful evaluation of the MacKenzie offer, the company and Host L.P. recommend that the holders of OP Units reject this unsolicited offer. In making this recommendation, the Company primarily considered that the offer price in the MacKenzie offer is below the $17.88 per share closing stock price of the Company's common stock on September 13, 2022. Although there is no trading market for the OP Units themselves, at any time holders of OP Units may request that the Company redeem their OP Units and the Company will issue 1.021494 shares of the Company's common stock in exchange for each OP Unit, which shares may then be sold. Based on the closing price of the Company's common stock on September 13, 2022 of $17.88, an OP Unitholder would receive shares with a market value of approximately $18.26 compared to the cash MacKenzie Offer of $13.00. The Purchaser has made many similar unsolicited mini-tender offers for equity of other companies and multiple earlier unsolicited mini-tender offers to holders of Host L.P. units at a similar discount to current market value. Like its other offers, this offer puts individual investors at risk because they may not realize they are selling their OP Units at a discount. The Company urges investors to get current quotes for the Company's common stock for which their OP Units may be redeemed, consult their financial and tax advisors and exercise caution with respect to the MacKenzie Offer. The Company recommends that OP Unitholders who have not responded to the Purchaser's offer take no action."

16:26 EDT PayPal CFO Jorgensen taking leave of absence - According to a regulatory filing, on September 14, 2022, PayPal Holdings announced that Blake Jorgensen, Executive Vice President and Chief Financial Officer, is taking a leave of absence for health reasons. The Board of Directors has appointed Gabrielle Rabinovitch to serve as the company's acting Chief Financial Officer and perform the duties of the principal financial officer of the company, effective immediately. Rabinovitch joined the company in April 2016. She currently serves as the company's Senior Vice President, Capital Markets, Investor Relations and Treasurer. Previously, she served as the company's interim Chief Financial Officer from May 2022 to August 2022, and as Senior Vice President, Corporate Finance and Investor Relations from September 2021 to September 2022. Prior to that, Rabinovitch served as the company's Vice President, Investor Relations.

16:22 EDT IronNet co-CEO William Welch resigns - IronNet said that Co-CEO William Welch will resign as co-CEO and from the Board of Directors in light of the restructuring of the business, and indicated he will continue to support the company in the short term. Chris Murphy, Head of Sales Operations, will lead the sales team in the interim, reporting to GEN (Ret.) Keith Alexander. Cameron Pforr has been appointed as IronNet's new Chief Financial Officer (CFO), replacing current CFO James Gerber who will be departing the company to join a private cybersecurity company.

16:21 EDT TechnipFMC awarded subsea contract by TotalEnergies - TechnipFMC has been awarded a "significant" engineering, procurement, construction and installation contract by TotalEnergies for its Lapa North East field in the pre-salt Santos Basin offshore Brazil. TechnipFMC will reconfigure and install umbilicals and flexible pipe in a new configuration that will further secure the production of the field. For TechnipFMC, a "significant" contract is between $75M and $250M.

16:20 EDT Ventoux CCM Acquisition Corp. holders approve business combination with Presto - Ventoux CCM Acquisition Corp., a special purpose acquisition company, announced that Ventoux's stockholders have approved its proposed merger with E La Carte, one of the largest labor automation technology providers in the hospitality industry, at a Special Meeting of its stockholders held on September 14, 2022. Approximately 99% of the votes cast at the Special Meeting, representing approximately 80% of Ventoux's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approve the Business Combination. The formal results of the Special Meeting will be included in a Current Report on Form 8-K to be filed by Ventoux with the Securities and Exchange Commission. The closing of the business combination is expected to take place on September 20, 2022. It is anticipated that the transaction will result in at least approximately $92.1 million in gross proceeds for the post-closing company, including proceeds from Ventoux's trust account and the previously announced committed private placement. Upon the closing of the Business Combination, the combined company (the "Company") will be renamed "Presto Automation Inc." and its common stock and warrants are expected to begin trading on the Nasdaq Stock Market beginning on September 21, 2022 under the ticker symbols "PRST" and "PRSTW" respectively.

16:18 EDT Arconic sees completing Extrusions segment review in Q3 - Arconic said that management expects to complete a business review of the Extrusions segment in the third quarter aimed at identifying alternatives to improve the financial performance of this segment in future periods. Such alternatives could include changes to the operations that may result in asset impairment charges. As of June 30, 2022, the aggregate carrying value of the Extrusions segment's properties, plants, and equipment, intangible assets, and operating lease right-of-use assets was approximately $230 million.

16:17 EDT Arconic sees Q3 adjusted EBITDA $135M-$150M - Third quarter 2022 Adjusted EBITDA is expected to be in the range of $135 million to $150 million. The third quarter results will be impacted by production outages and other operational challenges in Tennessee and Davenport that have reduced production from planned operating rates. Additionally, hyperinflationary energy costs are driving increased cost pressures and declining demand in Europe, which are expected to have an increasingly negative impact on third and fourth quarter results.

16:16 EDT PepsiCo, ADM form pact to support regenerative agriculture practices - ADM (ADM) and PepsiCo (PEP) announced a 7.5-year strategic commercial agreement to closely collaborate on projects that aim to significantly expand regenerative agriculture across their shared North American supply chains. This strategic partnership is expected to reach up to 2M acres by 2030, and represents a trailblazing effort by two global companies that share ambitious carbon reduction goals. The companies' capabilities span the food and agriculture value chains, creating a unique, large-scale platform to support farmers' transition to regenerative agriculture, while building their resilience to climate change. The long-term agreement will initially enroll corn, soy and wheat farmers across Kansas, Minnesota, Iowa, Illinois, Indiana and Nebraska, with the opportunity for future expansion, to increase visibility across the value chain and integrate a range of multi-year farmer-first regenerative agriculture initiatives, including cover crops, reduced tillage, nutrient management, diverse rotations, and responsible pesticide use. The companies plan to share resources and collaborate to create value throughout the supply chain by providing participants with technical and financial assistance, offering access to peer regenerative farming networks, hosting educational field days, and tracking results using trusted, third-party measurement systems. "Building a better food system is essential to the future health of the earth and all of us," said Jim Andrew, Chief Sustainability Officer, PepsiCo. "At its core, PepsiCo is an agricultural company, working to spread regenerative agriculture practices that restore the earth and reduce carbon emissions to 7 million acres by 2030. This partnership with ADM marks a sea change in how PepsiCo engages with strategic partners and is expected to help us reach almost one-third of that goal. By enabling greater collaboration through strategic partnerships like this one, we can strengthen the livelihoods and resilience of the farmers we work with, while building a more sustainable future together."

16:12 EDT PotlatchDeltic, CatchMark complete merger - PotlatchDeltic (PCH) "announced the successful completion of the previously announced merger of CatchMark Timber Trust (CTT) in an all-stock transaction, creating a leading integrated timber REIT. All closing conditions have been met. PotlatchDeltic also announced that James DeCosmo, who served on CatchMark's board since 2020, became a PotlatchDeltic director effective with the merger close. PotlatchDeltic's board now consists of 10 directors. In accordance with the terms of the merger agreement, each outstanding share of CatchMark common stock immediately prior to the merger converted to the right to receive 0.23 shares of PotlatchDeltic common stock. In total, approximately 11.5M shares of PotlatchDeltic common stock will be issued to CatchMark shareholders, representing approximately 14% of total shares outstanding. In conjunction with the merger, PotlatchDeltic refinanced $277.5M of CatchMark's debt and repaid another $22.5M of such debt."

16:08 EDT Kensington Capital Acquisition, Amprius Technologies complete merger - Amprius Technologies announced that it has completed its business combination with Kensington Capital Acquisition Corp. IV . The Business Combination was approved by Kensington shareholders in a special meeting held on September 13, and formally closed September 14. On September 15, Amprius' common stock will begin trading on the NYSE under the ticker symbol "AMPX" and Amprius' public warrants will trade under the ticker symbol "AMPX.W."

16:07 EDT Kevton Technologies acquires seven Velo3D printers - Velo3D "announced Kevton Technologies, a subsidiary of Houston-based contract manufacturer Kevton Industries, has acquired seven Sapphire printers to provide its customers with high-quality, additively manufactured parts. The purchase is one of the largest ever with Velo3D from a contract manufacturer and will make Kevton Technologies one of the top suppliers of additively manufactured parts relying on Velo3D's laser powder bed fusion technology. The first two Sapphire printers are scheduled to begin producing parts for customers in Q1, 2023 in Kevton's Houston, Texas facility."

16:06 EDT Laureate Education announces special cash distribution of 83c per share - Laureate Education announced that its board of directors approved, pursuant to the previously announced adoption of a plan of partial liquidation related to the distribution of net proceeds from the company's sale of Walden e-Learning, the payment of a special cash distribution equal to 83c per each share of the company's common stock, par value $0.004 per share, to each holder of record on September 28. The Distribution is scheduled to be paid on October 12. Based on the current number of shares outstanding, the aggregate amount of the Distribution is expected to be approximately $137M. The proceeds being distributed are attributable to the release of $71.7M of escrowed funds from the Sale plus remaining net proceeds that had yet to be distributed. This is anticipated to be the final distribution pursuant to the Plan.

16:06 EDT Qiagen, Neuron23 partner over LRRK2 inhibitor companion diagnostic - Qiagen and Neuron23 announced the signing of an agreement to develop a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase inhibitor for Parkinson's disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to a LRRK2 inhibitor. The partnership will support the clinical development of Neuron23's drug candidate that is currently in the late stages of preclinical development. Subject to further clinical development, the agreement also covers options for the future development of additional companion diagnostics. Neuron23 joins a group of more than 25 leading pharmaceutical and biotechnology companies who have reached master collaboration agreements with QIAGEN to develop and commercialize companion diagnostic tests for their drug candidates - a deep pipeline of potential future products to advance precision medicine for the benefit of patients around the world.

16:06 EDT Mondee Holdings Inc trading resumes

16:03 EDT Qiagen, Neuron23 announce collaboration on Parkinson's disease - Neuron23 and Qiagen announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. Under the Master Collaboration Agreement, Qiagen will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease patients to a LRRK2 inhibitor. The partnership will support the clinical development of Neuron23's drug candidate that is currently in the late stages of preclinical development. Subject to further clinical development, the agreement also covers options for the future development of additional companion diagnostics. The assay for this collaboration will be integrated into a next-generation sequencing workflow that leverages Qiagen's Sample to Insight capabilities. Parallel development of the diagnostic assay and the therapeutic will allow the companies to submit the application to the U.S. FDA for premarket approval of the NGS companion diagnostic test in tandem with the new drug application for Neuron23's LRRK2 inhibitor.

14:45 EDT Block says can address additional demographics with Cash App - Says Cash App has grown to 47M monthly active users and sees opportunities to address additional demographics with Cash App over time. Block executives are presenting at the Goldman Sachs Communacopia & Technology Conference.

14:15 EDT California AG sues Amazon over 'artificially high prices' - California Attorney General Rob Bonta announced his office had filed a lawsuit in San Francisco Superior Court against Amazon.com, alleging the company's contracts with third-party sellers and wholesalers lead to "artificially high" prices, reduce competition and violate the state's antitrust and unfair competition laws. The suit seeks to block Amazon from continuing those policies and to appoint a monitor to ensure compliance, according to a copy viewed by The Wall Street Journal. It also seeks unspecified damages for harm to the state economy and $2,500 for each violation of the state's civil and professional code proved at trial. "Amazon coerces merchants into agreements that keep prices artificially high, knowing full-well that they can't afford to say no," Bonta said. "We won't let Amazon bend the market to its will at the expense of consumers and the economy," he added.

13:55 EDT North American rail traffic up 1.5% for the week ending September 10 - The Association of American Railroads or AAR reported U.S. rail traffic for the week ending September 10. For this week, total U.S. weekly rail traffic was 464,261 carloads and intermodal units, down 0.9% compared with the same week last year. Total carloads for the week ending September 10 were 223,384 carloads, down 0.2% compared with the same week in 2021, while U.S. weekly intermodal volume was 240,877 containers and trailers, down 1.7% compared to 2021.Five of the 10 carload commodity groups posted an increase compared with the same week in 2021. They included motor vehicles and parts, up 3,251 carloads, to 13,373; grain, up 1,495 carloads, to 18,214; and farm products excl. grain, and food, up 720 carloads, to 15,695. Commodity groups that posted decreases compared with the same week in 2021 included metallic ores and metals, down 2,451 carloads, to 19,937; coal, down 2,432 carloads, to 67,492; and miscellaneous carloads, down 1,595 carloads, to 8,265. North American rail volume for the week ending September 10 on 12 reporting U.S., Canadian and Mexican railroads totaled 321,989 carloads, up 2% compared with the same week last year, and 323,856 intermodal units, up 1% compared with last year. Total combined weekly rail traffic in North America was 645,845 carloads and intermodal units, up 1.5%. North American rail volume for the first 36 weeks of 2022 was 24,341,405 carloads and intermodal units, down 2.4 percent compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:47 EDT McDonald's to open innovation lab at global headquarters - McDonald's Corporation is announcing the establishment of a new facility, Speedee Labs, which it said "will be focused on driving the customer experience and supporting restaurant teams through innovation," at its global headquarters located at 110 N. Carpenter Street in Chicago's West Loop neighborhood. McDonald's plans to relocate all jobs from its Innovation Center in Romeoville to MHQ's Speedee Labs, adding to its Cook County workforce, the company stated. Manu Steijaert, McDonald's Executive Vice President and Chief Customer Officer, added: "Just as the creation of McDonald's Customer Experience team brought key aspects of our business strategy together, the creation of Speedee Labs will enable more of our customers, restaurant teams, markets and global teams to contribute to our innovation, while driving growth and creating more seamless and memorable McDonald's experiences."

13:02 EDT Verizon drops 1% to $41.33 after Goldman Sachs conference presentation

13:01 EDT New Jersey Resources raises quarterly dividend by 7.6% to 39c per share - The board of directors of New Jersey Resources unanimously approved a 7.6% increase in the quarterly dividend rate to 39c per share from 36.25c per share, the company announced. The new quarterly rate will be effective with the dividend payable October 3 to shareowners of record on September 26.

13:00 EDT Verizon sees decline in wireless subscribers in Q3 - Comments taken from the Goldman Sachs Communacopia + Technology Conference.

12:50 EDT EA says 'The Sims 4' base game will be free-to-play starting October 18 - Electronic Arts (EA) said that, starting October 18, 2022, "The Sims 4" base game will be available to all new players to download for free on PC via EA app or Origin, Mac via Origin, Steam, PlayStation 5 (SONY), PlayStation 4, Xbox Series X S (MSFT) and Xbox One systems. "With The Sims 4 going free to play, our team is more dedicated than ever to developing new and meaningful The Sims 4 experiences for our players and we will continue to develop and release packs, kits and Sims Delivery Express drops into the foreseeable future," the company said. "We'll be sharing more about what's in the works during a special-edition stream, Behind The Sims Summit on October 18, 2022 at 10 am PDT via The Sims YouTube and Twitch channels, also available on demand!" The Fly notes that "The Sims 4" first launched in 2014. Reference Link

12:41 EDT Amazon announces new marketing solutions for DTC ecommerce sellers - Today at Accelerate, Amazon's annual seller conference, Amazon announced new marketing solutions that it said "enable direct-to-consumer ecommerce sellers to reach engaged Amazon shoppers and help drive sales on their own sites." Amazon is piloting the solutions as part of Buy with Prime, a new program that enables sellers to offer Prime shopping benefits to shoppers off Amazon, the company reported. "Direct-to-consumer online sellers struggle with two key pain-points: driving traffic and converting shoppers. With the launch of Buy with Prime, sellers have begun to increase conversion by offering shopping benefits that millions of Prime members love and trust-including fast, free delivery and a seamless checkout experience. Now, we're taking the next step by piloting marketing solutions to help Buy with Prime sellers attract more engaged shoppers to their sites," said Peter Larsen, Amazon's vice president of Buy with Prime. "Together, Sponsored Brands ads and the new Buy with Prime stores pages help Buy with Prime sellers reach relevant shoppers on Amazon and direct them to their own DTC sites. Both solutions are now available in an invitation-only beta," the company added.

12:01 EDT Poxel Autosomal Dominant Polycystic Kidney Disease treatment gets orphan status - A potential treatment of Autosomal Dominant Polycystic Kidney Disease being developed by Poxel S.A. has been granted FDA orphan designation, according to a post to the agency website. Reference Link

12:00 EDT Alcoa falls -9.3% - Alcoa is down -9.3%, or -$4.67 to $45.62.

12:00 EDT Nacco Industries rises 14.5% - Nacco Industries is up 14.5%, or $6.40 to $50.45.

12:00 EDT Raytheon Technologies sees R&D tax changes reducing FCF by $6B over 5 years

11:59 EDT Raytheon sees structural castings issues lasting through end of year

11:06 EDT Delta Air Lines CFO says September 'off to a really, really good start' - Speaking at the Morgan Stanley Laguna Conference, Delta Air Lines CFO Daniel Janki said he is "really happy with the progress that the Delta team has been making." Janki stated, according to a transcript of the event: "We talked about it back in July that we took a number of proactive actions in June to reset our second half schedule to set how we do crew scheduling, the set of operational buffers, our airport procedures. And as we progressed here through the summer, July was better than June operationally. August was better than July. And September month-to-date, it's off to a really, really good start to a point where we're running the mainline 99.96% completion factor, continue to lead the industry across those metrics year-to-date, month-to-date, quarter-to-date. So we're really proud of the progress that the team has made on that front and that we're making. You're seeing it from our customers. Our NPS is very strong. It's above what we targeted. And even our operational metrics is actually better. We didn't or talking about 2019 in a lot of ways, but in September, we're ahead of September of 2019 as it relates to operational performance. So really happy and pleased with where we are."

10:48 EDT iHeartMedia launches iHeartLand on Roblox - iHeartMedia (IHRT) opened the gates to iHeartLand on Roblox (RBLX). The company said, "iHeartLand is a one-of-a-kind place where gaming, live events, never-ending entertainment, music and the most popular talent converge to offer fans a premiere interactive experience. Users on Roblox will become music tycoons by collecting sound energy throughout iHeartLand to power their own customized music studio as well as unlock upgrades, fan experiences and rewards. Users can also visit different branded spaces like the State Farm Neighborhood featuring Jake from State Farm and Intel House of Wonder to engage with other avatars, play games and more."

10:34 EDT AMTD Digital Inc - ADR trading resumes

10:31 EDT LoanDepot appoints Gregory Smallwood as CLO - loanDepot announced Gregory Smallwood has joined the Company as chief legal officer and Corporate Secretary, effective immediately. He will report directly to loanDepot CEO Frank Martell. As chief legal officer, Smallwood will oversee all aspects of the Company's legal strategy, supporting loanDepot's focus on providing exceptional service to its customers, employees, and investors. Prior to loanDepot, Smallwood served as general counsel and executive vice president of Caliber Home Loans.

10:23 EDT Raytheon Technologies unit awarded Intelligence & Space contract by FAA - Raytheon Intelligence & Space, a Raytheon Technologies business, has been awarded a competitive indefinite delivery indefinite quantity contract from the Federal Aviation Administration with a ceiling value of $375M over the next 10 years. Task orders, valued at $215M, were executed at contract award to provide technical refresh and Dual Frequency Operation upgrades to the FAA's Wide-Area Augmentation System, or WAAS, a space-based precision navigation system, that will enhance safer air travel in support of the National Airspace System. Under the WAAS DFO-2 contract, RI&S will deliver more modern processing, system security, and network architecture, while also adding dual frequency service.

10:13 EDT Ventoux CCM Acquisition Corp trading resumes

10:02 EDT Cinedigm announces deal with Vidgo to expand Cineverse distribution - Cinedigm announced a new deal with Vidgo, which it said will become "the first virtual MVPD to agree to distribute Cinedigm's flagship streaming service, Cineverse, which will feature a lineup of free ad-supported streaming television channels plus thousands of films and TV series on demand." Vidgo plans to launch Cineverse this Fall, Cinedigm stated.

10:00 EDT Li-Cycle falls -10.8% - Li-Cycle is down -10.8%, or -77c to $6.34.

10:00 EDT Earthstone Energy rises 8.3% - Earthstone Energy is up 8.3%, or $1.25 to $16.23.

10:00 EDT W&T Offshore rises 10.7% - W&T Offshore is up 10.7%, or 72c to $7.44.

09:47 EDT Flowserve falls -6.7% - Flowserve is down -6.7%, or -$2.05 to $28.74.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -9.6% - ProShares UltraShort Bloomberg Natural Gas is down -9.6%, or -$1.17 to $11.05.

09:47 EDT W&T Offshore rises 6.0% - W&T Offshore is up 6.0%, or 41c to $7.12.

09:42 EDT NeuroBo Pharmaceuticals trading halted, volatility trading pause

09:41 EDT ADiTx Therapeutics trading resumes

09:37 EDT Procore, Quickbase partner for no-code toolkit for enhanced workflows - Quickbase announced a new partnership with Procore Technologies. The partnership empowers Procore users with a powerful no-code toolkit to create unique, real-time applications to enhance workflows and unlock new possibilities within Procore, all without the need of professional developers.

09:36 EDT ADiTx Therapeutics trading halted, volatility trading pause

09:34 EDT Save Foods announces new sales with Mexican lime packers - Save Foods announced new commercial adoption of its eco-crop protection treatment by Mexican lime packers following the recent successful completion of several pilot programs in Veracruz, Mexico.

09:31 EDT Kits Eyecare launches same-day delivery - Kits Eyecare announced that same-day delivery is now available in Vancouver and across the lower mainland on over 70% of products available on KITS.ca. Prescription eyeglasses and contact lens orders received before 12pm are eligible for delivery the same day.

09:27 EDT TEN, Ltd. declares dividend of 15c per share - The Company continues the uninterrupted payments of common stock dividends with a new distribution of $0.15 per common share scheduled for December 2022. This reflects the second payment for 2022 which is in line with the TEN's semi-annual dividend policy and represents a 50% increase from the prior base of $0.10 paid in July 2022. Inclusive of this upcoming distribution, TEN has paid common shareholders half a billion dollars in dividends, equating to about $25 million per annum since its 2002 NYSE listing. During the second quarter of 2022, the Company issued, through its ATM program, 460,569 common shares generating $4.8 million.

09:25 EDT DigitalBridge reinstates dividend with 1c per share - DigitalBridge Group, announced that its Board of Directors has reinstated the Company's quarterly dividend, declaring a cash dividend of 1c per share. The dividend will be payable on October 17 to shareholders of record at the close of business on September 30. "We are pleased to follow through on another commitment to our shareholders and reinstate our quarterly cash dividend," said Marc Ganzi, CEO of DigitalBridge. "Successful execution against our strategic objectives has strengthened DigitalBridge's cash flow profile and significantly improved our long-term earnings potential. While management continues to prioritize reinvesting capital in the company's growth-focused strategy, the addition of a dividend enhances total shareholder return." About DigitalBridge

09:23 EDT Rennova Health provides business update - The company said, "Rennova Health CEO Seamus Lagan joined Stock Day host Everett Jolly to provide an update on the business and future plans. Jolly began the interview by referring to the most recent 10Q filed by the Company and noting the improved net revenues and financial condition. He asked if the Company expected to have profitable operations going forward. Lagan responded by confirming that the hospital operations were significantly improved and that he believed that hospital operations would be profitable going forward. He also cautioned that a significant amount of legacy debt and other liabilities remained but pointed to the improvements made in the past year and his belief that improvements would continue. Jolly asked for an update on the recently disclosed plan to expand the business into providing behavioral health services. Lagan confirmed the intention to move forward with this initiative and stated that the Company had recently hired an experienced individual to head up this new business. He also confirmed a focus of the new management in creating a detailed business plan that would, in part identify capital needs, and reminded his listeners that the business would utilize available space in the Company's existing properties. Jolly then asked for an update on the shares of common stock outstanding and asked Lagan if the Company had any plans to effect another reverse stock split. Lagan stated that there were approximately ten billion shares issued and outstanding and that there were two hundred and fifty billion shares authorized meaning that there was no need for a reverse split for the foreseeable future. He confirmed that the Company currently had no plans to complete a reverse split. Jolly ended the interview by asking Lagan what message he would like the Company's shareholders to take away from the interview. Lagan responded by referring to previous disclosures of the intention to stabilize the business and his belief that operations have now been stabilized, and that a capable and experienced management team was now in place, allowing the business to focus on building the behavioral health division and possibly looking at additional acquisitions again going forward."

09:18 EDT Celcuity appoints Polly Murphy to board of directors - Celcuity announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors. Murphy is currently the Chief Business Officer of UroGen Pharma, where she has served since 2020, and a member of Atea Pharmaceuticals' Board of Directors.

09:16 EDT Sumo Logic adds Cloud SIEm to FedRAMP-moderate offering - Sumo Logic announced that Sumo Logic Cloud SIEM is now available as part of the Sumo Logic FedRAMP-Moderate offering. With this designation, Sumo Logic becomes the first cloud-native SIEM to deliver insights into on-premises and cloud environments for public sector organizations to help them navigate the growing global threat landscape. Sumo Logic also announced that it expanded its partnership with CloudHesive, a cloud-based Managed Security Services Provider. "The public sector is advancing to deliver rapid innovation, reliable processes, and ensure secure, agile delivery," said George Gerchow, CSO and SVP of IT, Sumo Logic. "Our relationship with CloudHesive is a natural step forward to help federal and public sector agencies. Together, we will bring cloud-native technologies to enable public sector and higher education institutions to make the right investments, navigate complexity and realize value quickly."

09:13 EDT Westhaven Gold arranges financing package with Franco-Nevada - Westhaven Gold (WTHVF) is pleased to announce that it has entered into a financing arrangement with Franco-Nevada Corporation (FNV). Westhaven has agreed to sell a 2% net smelter return royalty to Franco-Nevada for $6,000,000. The NSR applies to all of Westhaven's claims across the Spences Bridge Gold Belt in Southwestern British Columbia, Canada. Westhaven has an option to buy-down 0.5% of the NSR for $3,000,000 for a period of 5 years from the closing of the transaction. Westhaven has also agreed to sell to Franco-Nevada for $750,000 the Talisker Resources Ltd. net smelter return royalty originally granted to Westhaven by Sable Resources. In addition, Franco-Nevada has agreed to subscribe for 2,500,000 shares of the Company at a price of C$0.40 for gross proceeds of C$1,000,000.

09:11 EDT Wrap announces new footage of successful deployment of BolaWrap device - Wrap Technologies shared new agency body cam footage demonstrating another successful outcome from the deployment of the BolaWrap Remote Restraint device. On September 4, 2022, officers of the LaGrange Police Department in Georgia responded to a call of a man acting erratic in the area while operating a vehicle. When the officers arrived on-scene, it was determined that he was under the influence of drugs. The subject was noncompliant and attempting to walk away from the officer's commands. The BolaWrap was deployed to the subject's legs and immediately changed the subject's behavior and de-escalated the situation. "The officers on the scene did a great job of reading the situation and executing the proper deployment of the BolaWrap," said Wrap CEO, TJ Kennedy. "The trained officers of the LaGrange Police Department were able to take a chaotic situation and de-escalate the situation by using the BolaWrap. Each time we see another successful field use, we are encouraged by the real-world evidence that supports our mission to help save lives and careers."

09:09 EDT Fresh Vine announces Food Lion has added its varietal program at 225 locations - Fresh Vine Wine announced that Food Lion has added its California Cabernet Sauvignon varietal to its 'Limited Reserve' program at 225 Food Lion grocery locations in North Carolina, South Carolina, and Virginia. "I am delighted to announce that Food Lion has chosen Fresh Vine Wine's 92 point rated California Cabernet Sauvignon as the newest addition to its celebrated 'Limited Reserve' collection of fine wines," said Bill Donovan, East Atlantic Division Manager, Fresh Vine Wine. "Food Lion enjoys a leading position in the Grocery Market in its geographic markets, where it is focused on offering its customers fresh, healthy food and beverage choices. The introduction of our 'Better For You' California Cabernet Sauvignon furthers their effort to meet this growing demand for healthy choices without compromising taste. As part of our national grocery channel rollout strategy, Food Lion complements our existing footprint and provides us with premier retail distribution in the Southeastern U.S."

09:08 EDT Centessa announces ODD granted to SerpinPC for treatment of hemophilia B - Centessa Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to SerpinPC, a novel inhibitor of activated protein C, APC, for the treatment of hemophilia B. Centessa plans to begin registrational studies of SerpinPC in the fourth quarter of 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins that is designed to allow more thrombin to be generated by inhibiting APC, thus rebalancing coagulation in hemophilia patients. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa. "This designation from the FDA is an important milestone in the development of SerpinPC and underscores the need for new, innovative treatment options for patients with hemophilia B. We look forward to initiating registrational studies for SerpinPC later this year, as well as reporting the two-year follow-up data from the SerpinPC Phase 2a open label extension study in the fourth quarter."

09:06 EDT Progress Software announces latest release of developer tools portfolio - Progress announced the latest release of its developer tools portfolio, including Progress(R) Telerik(R), Progress Kendo UI and Progress Telerik Test Studio. With today's R3 2022 release, Progress introduced Progress ThemeBuilder Pro, enabling developers and designers to implement design systems seamlessly in web applications, delivering a greater level of design consistency without manual coding work. The company also announced advanced capabilities for the top development frameworks including Blazor, .NET MAUI, Angular and React to help developers build consistent, high-quality and accessible UI.

09:05 EDT Sidus Space, Momentus sign MOU to explore launch collaboration - Sidus Space (SIDU) announced that it has signed a memorandum of understanding, or MOU, with Momentus (MNTS) to explore launching its LizzieSat satellites utilizing Momentus' Vigoride Orbital Service Vehicle, or OSV. The MOU also seeks to foster collaboration between the two companies to use their joint capabilities to seek new opportunities together, expanding both firms' reach. Together the firms are discussing undertaking an integrated mission that has characteristics of both a Hosted Payload and Delivery Service. Once in orbit, a Momentus OSV could provide power and data to LizzieSat for deployment, offering mission versatility for customers based on Vigoride's service capabilities in-orbit. Sidus Space is interested in four potential mission launches with Momentus initially. As part of the MOU, the companies will potentially provide and/or source payloads to one another and explore working together on select government solicitations.

09:05 EDT Twilio reducing workforce by approximately 11%

09:04 EDT Future Publishing appoints Clair Blunt as COO - Future Publishing announced the appointment of Claire Blunt as COO. Claire is currently Chief Advertising Officer and CEO of International for the Guardian Media Group.

09:02 EDT PubMatic enters into definitive agreement to acquire Martin - PubMatic announced that it has entered into a definitive agreement to acquire Martin, a media measurement and reporting platform, deepening the company's investment in supply path optimization, SPO. "The digital advertising supply chain of the future must be efficient and effective for both publishers and buyers alike. To this end, over the past several years we have been investing in technology and solutions to enable buyers to efficiently access inventory and audiences from top publishers around the globe," said Rajeev Goel, co-founder and CEO at PubMatic. "By integrating Martin's robust workflow, analytics and optimization capabilities for advertisers and agencies into our platform, we believe we will further accelerate and solidify our position as the platform of choice for buyers, and in turn bring greater advertising revenue to our global publisher base." The acquisition is in response to growing demand from PubMatic's buy-side customers for enhanced tools to take advantage of PubMatic's global omnichannel inventory, including market-leading addressability solutions like Connect and innovative technology to enable SPO. The transaction will be fully funded from existing cash on PubMatic's balance sheet, and is expected to close in mid-September 2022, subject to customary closing conditions.

09:00 EDT Maxpro Capital Acquisition Corp trading resumes

08:50 EDT U.S. Gold submitts application for permit to mine for CK Gold Project - U.S. Gold reported that it has submitted an application for a Permit to Mine and the Mine Reclamation Plan to the Wyoming Department of Environmental Quality, or WDEQ, for its proposed CK Gold Project, 20-miles west of Cheyenne. The application and fees were delivered to the WDEQ office on Friday, September 9, 2022, and the initial electronic data transfer of the information supporting the application was provided on Tuesday, September 13, 2022, through access to a data site. The proposed Project has reached an advanced state of engineering, following the publication of the Prefeasibility Study on December 1, 2021, which supports permit submissions. The key permit application is the Permit to Mine and Mine Reclamation Plan, both of which are now available for the WDEQ to start reviewing. Initially, the WDEQ will conduct a completeness review and provide the Company with any deficiencies in content. Thereafter, the technical review process will start, addressing comments and questions that the department might have, which includes commentary that might come from other governmental agencies and the public. The Company, as applicant, may need additional time to respond to questions or provide clarification requested as part of the review. Hence, there is no definitive time as to when a decision will be made with respect to the outcome of the application. For projects where the capital investment exceeds $253.8M, approval is required by the Industrial Siting Division, a department within the WDEQ.

08:46 EDT Portage Biotech provides research and development update - Portage Biotech provided an update on its research and development programs for its expanded portfolio of immuno-oncology assets, and outlined its forward-looking clinical development goals for the next two years. The company remains focused on advancing two broad platforms, its invariant natural killer T cell agonists and its newly acquired adenosine antagonists, PORT-6 and PORT-7. COVID-related backlogs for activating clinical trial sites and staff shortages have made expansion of the PORT-2 study in the United Kingdom challenging. As a result, the company has prepared a parallel company-sponsored study, IMPORT-201, to be launched in the United States and European Union to mitigate the slowdown in the United Kingdom. This will enable more control of progress on the trials and will also impact timing of data readouts. Ongoing development programs are as follows: iNKT Portfolio - Activating the innate, adaptive immune systems and correcting the tumor microenvironment: PORT-2: The newly designated IMPORT-201 study is a multi-arm study Phase 1/2 trial evaluating PORT-2 in non-small cell lung cancer and refractory melanoma; Data presented at the 2022 American Society of Clinical Oncology meeting in June confirmed MOA and demonstrated preliminary safety , tolerability and single agent activity. During ongoing discussions with melanoma thought leaders in the U.S. and EU, it became clear that the front-line standard of care for melanoma is different in the U.S. than in the UK. As a result, the Company has made a strategic decision to drop the front-line randomized melanoma arms of this study and recruit more patients into the front-line NSCLC randomized comparison portion of the study. The Company anticipates four Phase 2 efficacy readouts from the IMPORT-201 study in both NSCLC and melanoma in 2023 and 2024. PORT 3: The Horizon grant that was funding the PRECIOUS study has ended. The Company is waiting for additional data to determine next steps for development. Adenosine Portfolio - Modulating adenosine pathway in four different ways to determine the optimal approach to maximize the impact mechanism of action on different tumors: The Company believes that leveraging the A2A and A2B pathways, alone or in combination, holds the potential for customized treatment for specific patients and/or tumor types. PORT-6 is a potent, selective and durable A2A antagonist while PORT-7 is a highly selective and potent A2B antagonist. The ADPORT-601 adaptive Phase 1a/1b study will explore PORT-6 and PORT-7 as monotherapies, in combination with one another and possibly in combination with other Portage assets. Phase 1b is designed to explore PORT-6 and PORT-7 monotherapies in an enriched population and in randomized trials vs. standard of care. There is strong interest from academic collaborators in the upcoming ADPORT-601 study and the Company is in the process of setting up multiple collaborations on the platform. The Company also recently announced that the U.S. National Cancer Institute has amended its Cooperative Research and Development Agreement to test the products targeting the adenosine pathway. Clinical Development Goals & Anticipated Readouts: Q4 2022: Data from IMPORT-201 study to be presented at a major scientific conference in November; Activation of the ADPORT-601 adaptive Phase 1a/1b study of PORT-6 in multiple tumor types. 2023: Initiation of IMPORT-201 Phase 2 trial Q1; Submission to a major oncology conference with update on IMPORT-201 data Q2; Addition of PORT-7 in the ADPORT-601 Phase 1a/1b study in multiple tumor types 1H; ADPORT-601 data and IMPORT-201 data presented at a major medical conference Q4. 2024: IMPORT Phase 2 ORR data submitted to a medical conference 1H; ADPORT-601 Phase 1b trial initiation 2H; IMPORT Phase 2 PFS data submitted to a medical conference 2H.

08:38 EDT Bioaffinity presents its research in flow cytometry analysis of sputum - BioAffinity Technologies announced publication of its research in high-throughput flow cytometry analysis of sputum. The journal PLOS ONE, published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung. "The PLOS ONE paper presents our unique method for determining the health of an individual's lungs," bioAffinity President and CEO Maria Zannes said. "Flow cytometry allows for analysis of whole cells and cell populations that make up the lung environment. Our research provides a better understanding of how disease changes the lung environment and how flow cytometry can be used as a diagnostic tool by analyzing sputum. Flow cytometry is successfully used to diagnose blood cancers, particularly at early stage. In the paper, we describe an innovative and highly efficient method to analyze sputum for the presence of lung cancer, with the potential to focus on other diseases such as COPD and asthma."

08:36 EDT KULR Technology announces it has joined NAATBatt International - KULR Technology Group announced it has joined NAATBatt International, NAATBatt, the trade association of developers, manufacturers, suppliers and users of battery technology in North America. As a platinum member, KULR will regularly participate in board meetings, allowing the company to connect with top policy makers in the space, discuss and develop cutting-edge technological advancements and remain at the forefront of battery technology. "KULR is at an inflection point as we position our thermal safety solutions platform to become further entrenched in the marketplace, ultimately providing us with an opportunity to optimize logistics as we continue investing in the localization of our production and supply chain to North America," said Michael Mo, Co-Founder and CEO of KULR Technology Group. "Becoming a member of NAATBatt allows us to further that mission. We'll learn and participate in the development of innovative solutions for the advancement of battery technologies, become better positioned to meet market needs and benefit from local policy support."

08:35 EDT Apollomics, Maxpro Capital Acquisition enter business combination agreement - Apollomics and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market. The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol "APLM." Apollomics' broad pipeline of drug candidates includes late-stage clinical assets for the treatment of patients with difficult-to-treat cancers. Apollomics' mission is to develop assets in critically important areas of unmet need. The Company's leading drug candidates address certain subpopulations within lung cancer and leukemia. Globally, both lung cancer and leukemia affect over 2 million people annually. The Company is dedicated to discovering and developing oncology therapies of different mechanisms of action to inhibit cancer. Its diverse portfolio of innovative drug candidates for treating difficult-to-treat cancers includes precision therapy targeting tumors with specific mutations, as well as assets addressing broader cancer conditions. The Company's pipeline of nine clinical, preclinical and discovery drug candidates has the potential to improve treatment of a number of tumor types. Upon the closing of the transaction, Apollomics will continue to be led by current Chairman and CEO, Dr. Guo-Liang Yu, Ph.D., a serial entrepreneur, and his team. Dr. Yu is a pharmaceutical researcher with more than 300 patents. Apollomics expects results from its global Phase 2 multi-cohort clinical trial of vebreltinib in NSCLC and other solid tumors with cMET dysregulation in 2023, which the Company believes may support its first New Drug Application with the U.S. Food and Drug Administration while generating clinical data for different indications. In addition, the Company expects to complete patient recruitment of its uproleselan Phase 3 study in China in 2023. Upon the closing of the Transaction, Apollomics will become a publicly traded company under the name "Apollomics Inc." The Transaction reflects an implied pre-money equity value of approximately $899M. Upon the closing of the Transaction and assuming no redemptions by Maxpro's public stockholders, Apollomics plans to retain up to $105M of cash, being expected proceeds from realization of marketable securities held in the Trust Account, on its balance sheet, which would provide financial flexibility and facilitate internal and external growth opportunities. At the closing of the Business Combination and assuming no redemptions by Maxpro's public stockholders, approximately 10% of the outstanding shares of the combined company are expected to be held by public investors, with existing Apollomics shareholders owning approximately 87%. The Transaction has been unanimously approved by the boards of directors of Maxpro and Apollomics. The completion of the Transaction is subject to customary closing conditions, including the approval of Maxpro's stockholders and the satisfaction of a $20M minimum cash condition. The Transaction is expected to close during the first quarter of 2023.

08:33 EDT MGP Ingredients names Landherr Chief Legal Officer - MGP Ingredients has named attorney Curtis Landherr as its Chief Legal Officer, CLO. Landherr brings over 25 years of law firm and in-house legal experience across a variety of industries to the new role, which he will start October 17, 2022. Most recently, Landherr served as Senior Vice President and General Counsel at Cirrus Aircraft where he created, managed and grew the legal function beginning in 2014.

08:33 EDT Commvault appoints Alan Atkinson as Chief Partner Officer - Commvault announced that data protection industry veteran Alan Atkinson has joined the company as Chief Partner Officer. Atkinson will report to Riccardo Di Blasio, Commvault's Chief Revenue Officer. Atkinson brings a wealth of cloud and data protection experience to Commvault - from building the industry's first, pre-eminent cloud service provider to leading WysDM Software until it was acquired to driving technology strategy and commercial sales at Dell. Under his leadership, Commvault will further strengthen the company's strategic alliances with cloud partners and continue to galvanize and grow its partner program.

08:32 EDT PFSweb deploys pop-up fulfillment operation for L'Oreal brand SkinCeuticals - PFS, a premier eCommerce order fulfillment provider and business unit of PFSweb (PFSW), announced they recently deployed a pop-up fulfillment center for one of their L'Oreal (LRLCY) USA brands, SkinCeuticals."This project was a fantastic example of the flexibility and efficiency our fulfillment innovations bring to the market," commented Zach Thomann, COO and President of PFS. "RetailConnect and our other fulfillment-as-a-service products are created using the same technology and processes deployed within our core order fulfillment operations. With a lightweight design and simple integration, they can be deployed into numerous working environments to facilitate an effective and cost-efficient pick-pack-ship operation. We appreciate the opportunity SkinCeuticals gave us to demonstrate the effectiveness of RetailConnect in solving their challenge and look forward to additional opportunities in the future."

08:29 EDT Rigetti Computing launches Rigetti QCS on Microsoft's Azure Quantum platform - Rigetti Computing announces that it has launched Rigetti QCS in Public Preview on Microsoft's Azure Quantum platform. Previously in Private Preview, all Azure Quantum users can now access Rigetti's Aspen-M-2 80-qubit and Aspen-11 40-qubit superconducting quantum processors on demand to develop and run quantum applications.

08:28 EDT Altimmune down 58% in pre-market after results of Phase 1b study of pemvidutide - Shares of Altimmune are down 57% or $11.58 at $8.80 in pre-market trading after the company announced topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease, NAFLD, even though the trial met its primary endpoint in all pemvidutide treatment groups.

08:22 EDT RiceBran regains compliance with Nasdaq bid price rule - RiceBran Technologies received formal notification from The Nasdaq Stock Market that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's common stock to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's common stock was at $1.00 per share or greater for the prior 10 consecutive business days. Nasdaq had previously notified the Company of its non-compliance with Listing Rule 5550(a)(2) on September 15, 2021. In accordance with its Listing Rules, Nasdaq afforded the Company 180 calendar days to regain compliance. On March 15, 2022, the Company received a 180-day extension from the Nasdaq to meet continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive business days. The Company had until September 12, 2022 to meet Nasdaq's Minimum Bid Rule. Prior to the expiration of the compliance period, the Company successfully regained compliance with the listing standard.

08:20 EDT Osisko Mining files technical report for Windfall MRE update - Osisko Mining is pleased to announce that it has filed a technical report in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects to update the mineral resource estimate on its 100% owned Windfall gold deposit. The technical report entitled " Mineral Resource Estimate Update for the Windfall Project, Eeyou Istchee James Bay, Quebec, Canada" and dated September 14, 2022 has been prepared for Osisko by BBA Inc. The technical report is available on SEDAR under Osisko's issuer profile. The technical report contains a non-material change from the news release published on August 30, 2022. Sensitivity Table 1 has been corrected for the 2.5g/t cut-off grade. This change does not impact the results of the August 30, 2022 news release as the modification affects only numbers presented for reference purposes in the news release. The NI 43-101 Technical Report cut-off grade has been determined with reference to a 3.5g/t cut-off grade.

08:18 EDT Freshworks director buys $11.5M in common stock - In a regulatory filing last night, Freshworks disclosed that its director Sameer Gandhi bought 786.6K shares of common stock on September 9th in a total transaction size of $11.5M. Shares of Freshworks are up 3.4% in pre-market trading at $14.90.

08:17 EDT BASF, X-ELIO sign power purchase agreement for Freeport site - BASF and X-ELIO have signed a 12-year Power Purchase Agreement to supply 48 megawatts of solar power to BASF's Verbund site in Freeport, Texas. With this agreement in place, 100% of the site's expected purchased power will be supplied from renewable energy. The project will further reduce carbon emissions at the BASF Freeport site and offset more than 82,000 metric tons of CO2 emissions annually, based on EPA estimates. Freeport is one of BASF's six global Verbund sites, which takes an integrated approach to manufacturing, research and the overall management philosophy. Together with the maximum integration of infrastructure, processes, talent, energy and waste management, this philosophy creates a highly efficient manufacturing site.

08:15 EDT Immutep sees cash runway into early 2024 - Including the planned program expansion, Immutep remains well-funded with ~$80 million in cash as of 30 June 2022, providing a cash runway into early CY2024.

08:13 EDT LifeMD expands primary care platform's diagnostic capabilities - LifeMD (LFMD) announced the continued expansion of its primary care platform's diagnostic capabilities with new offerings that include at-home screening kits for early warning signs of colon and breast cancer. LifeMD's new offerings feature the Aware Breast Self Exam pad for breast exams and the EZ Detect at-home test that can detect an early warning sign of colon cancer. Both kits are from Biomerica (BMRA). "We believe telehealth can play an essential role in diagnostic care and early detection as part of regular medical self-care, which is why LifeMD offers these at-home screening kits for free as part of the LifeMD membership. We're thankful for our strategic partnerships that allow us to provide innovative treatments and diagnostics to our patients," continued LifeMD CEO Justin Schreiber.

08:12 EDT Aldeyra provides update on pre-NDA meeting for RASP modulator reproxalap - Aldeyra announced that, following the recent receipt of official minutes from its pre-NDA meeting with the FDA, the company remains on schedule to submit an NDA in the fourth quarter of 2022 requesting marketing approval of the novel RASP modulator reproxalap, an investigational new drug, for the treatment of dry eye disease. Consistent with prior guidance, with results from five adequate and well-controlled completed clinical trials, Aldeyra intends to submit the NDA with data for ocular dryness symptom score, ocular redness, Schirmer test, and Schirmer test greater than or equal to10 mm responder analysis. The NDA efficacy package is expected to include activity ranging from within minutes of drug administration to up to 12 weeks of treatment, crossover and parallel-group clinical trial designs, and assessment in dry eye chamber challenge and natural environment settings. In addition to efficacy data, Aldeyra plans to submit up to 12 months of safety data. Topical ocular reproxalap has been studied in more than 2,000 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials. In addition to the planned NDA submission for reproxalap in dry eye disease, Aldeyra highlighted the following expected upcoming corporate milestones: The pre-NDA meeting for ADX-2191 for the treatment of primary vitreoretinal lymphoma has been scheduled for the fourth quarter of 2022. Results from Part 1 of the Phase 3 GUARD trial of ADX-2191 in proliferative vitreoretinopathy are expected in the third or fourth quarter of 2022. Results from the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa are expected in the first half of 2023. Results from the Phase 3 INVIGORATE-2 trial of reproxalap in allergic conjunctivitis are expected in 2023.

08:10 EDT Mindset Pharma receives scientific advice from MHRA on Phase 1 trial of MSP-1014 - Mindset Pharma announced that the Company has received Scientific Advice from the UK Medicines and Healthcare products Regulatory Agency on a range of points to finalize its Phase 1 first-in-human clinical trial plan evaluating its lead psychedelic drug candidate MSP-1014 for the treatment of Major Depressive Disorders. In a meeting with the MHRA, Mindset discussed its plans for Phase 1 first-in-human clinical development of MSP-1014, a novel and patented, second-generation psilocybin-like drug candidate within Family 1, in collaboration with a specialized psychedelic UK-based Contract Research Organization, Clerkenwell Health. The MHRA has agreed with the Company's position and confirmed that, subject to CTA review, MSP-1014 will not require additional preclinical studies at this time. The MHRA has also provided specific valuable guidance on potential clinical trial design regarding dosing, patient selection criteria, and safety endpoints. In preclinical studies, MSP-1014, demonstrated an improved efficacy and safety profiles, with reduced potential side effects and faster onset of action, and similar duration of effect compared to the first-generation drug candidate psilocybin. Given its differentiation and improved pharmacological profile, Mindset prioritized moving MSP-1014 to first-in-human clinical studies.

08:09 EDT Turquoise Hill says federal court in NY dismisses all claims from class action - Turquoise Hill Resources announces that a federal court in New York has dismissed all claims made against the Company and three of its current or former executives in a putative class action, backed by Pentwater Capital Management , filed in October 2020. The lead plaintiff in the case, a group of private investment funds advised by Pentwater alleged in its complaint that the Company and three of its executives had violated United States securities laws by making false or misleading statements about the progress and expected cost of the development of the Oyu Tolgoi underground mine in Mongolia. The Pentwater Funds brought the claims on behalf of a putative class of investors who purchased Turquoise Hill securities from July 17, 2018, to July 31, 2019, in the United States.

08:08 EDT Bionano Genomics announces publication of study in MDS, AML - Bionano Genomics announced the publication of a study evaluating the performance of OGM for detection of cytogenetic abnormalities in myelodysplastic syndromes and acute myeloid leukemia samples. This work is the second independent study, following a recent publication from researchers at MD Anderson Cancer Center, showing that OGM enables better molecular characterization of MDS. This paper extends that research to AML and the findings indicate that OGM may have an even greater impact on the characterization of AML compared to MDS, which led the researchers to recommend integrating OGM into new prognostic scoring methods for both myeloid malignancies. In the study published in Blood Cancer Journal, researchers analyzed samples from 68 adult MDS and AML patients using OGM to evaluate OGM's performance in the detection of cytogenetic abnormalities that may impact diagnosis and stratification into groups for treatment. In 33% of MDS samples and 54% of AML samples, the study reported more clinically relevant variants were detected using OGM than were found by traditional cytogenetic methods and these variants were reported to be highly relevant to the understanding of pathogenesis of these disorders. Additional findings of the study: The R-IPSS score was changed for 6 cases, which could impact prognosis or assist in patient stratification. In 8 cases, OGM found clinically significant events. OGM also detected balanced structural variants identifying partner genes of driver genes not routinely identified by other techniques.

08:06 EDT Dave & Buster's to open 11 units across KSA, UAE, Egypt - Just a few months after announcing its international expansion plans Dave & Buster's inks its first multi-country, multi-unit deal. The Brand will begin its expansion with sites in the Kingdom of Saudi Arabia, followed by the United Arab Emirates and Egypt.

08:05 EDT CrowdStrike Appoints Jennifer Johnson as CMO - CrowdStrike (CRWD) announced the appointment of Jennifer Johnson as the company's new chief marketing officer . Leveraging a 20-year track record in software marketing with expertise in cybersecurity and IT management, Johnson is a seasoned CMO who has earned a reputation as a bold storyteller well known for helping companies define and dominate market categories. She has run global marketing for leading cybersecurity and technology organizations including Tenable (TENB) and Amplitude (AMPL) - both of which she helped lead through successful public offerings - as well as Coverity (now Synopsys) and Tanium. Most recently, she served as CMO at Illumio, and previously served on the Illumio Board. Johnson also served as a partner at Andreessen Horowitz and a Category Designer in residence at Play Bigger, where she helped clients introduce radically different go-to-market approaches, hone their strategic positioning and disrupt existing markets. She currently serves on the Board of Immersive Labs.

08:04 EDT Timber Pharmaceuticals receives positive COMP opinion for TMB-001 - Timber Pharmaceuticals announced that the Committee for Orphan Medicinal Products at the European Medicines Agency issued a positive opinion on the Company's application for orphan designation for TMB-001 for the treatment of autosomal recessive congenital ichthyosis. Based on the COMP's opinion, the European Commission is expected to issue its decision on the orphan designation in approximately 30 days.

08:03 EDT Comcast increases share repurchase authorization to $20B - Comcast announced that its board of directors has increased its share repurchase program authorization to a total of $20B, effective as of September 13. The authorization does not have an expiration date. To date during 2022, Comcast has repurchased $9B of its Class A common stock.

08:02 EDT Cerence selected by CFMOTOT to bring coversational AI to two-wheelers, ATVs - Cerence announced that CFMOTO has selected Cerence for conversational AI-powered interaction with its two-wheelers and ATVs, marking a major strategic win for Cerence Ride, the company's conversational AI platform for two-wheelers. As two-wheeler ridership expands worldwide and as consumers turn to ATVs for safe, outdoor fun, CFMOTO's partnership with Cerence will transform the motorcycle and ATV experience, empowering its riders with the information they need - including two-wheeler-centric, voice-powered navigation; system controls and diagnostics via voice; and cloud-based content - in a safe manner while minimizing distractions. "The motorcycle and ATV experience has long been in need of enhancements that make riding safer and more delightful by using the same conversational AI that car owners have experienced for years," said Siva Subramanian, SVP, Connected AI & Mobility, Cerence. "We are proud to partner with CFMOTO as they transform the experience for their riders through AI-powered technologies that enhance their safety, comfort, and enjoyment."

08:01 EDT Choice Hotels raises number of shares for repurchase program - Choice Hotels International announced that its board of directors has approved an increase in the number of shares authorized under its share repurchase program by five million shares. When added to the remaining number of available shares previously authorized for repurchase, this results in a total authorization of approximately 6.7 million shares.

07:50 EDT Great Panther Mining receives delisting notice from NYSE American - Great Panther Mining reports that it has a received a letter from the New York Stock Exchange notifying the company that as a result of the filing of a notice of intention to make a proposal under the Bankrupcy and Insolvency Act and in accordance with the NYSE American Company Guide, NYSE Regulation has determined that the company's common shares will be delisted from the NYSE American. The NYSE also notified the company that trading of the Shares has been halted as of September 13, 2022. The company has elected not to appeal NYSE Regulation's determination. A Form 25 will be filed with the SEC, which will remove the Shares from listing and registration on the NYSE. The company expects that its Shares will be eligible to be quoted on the OTC Pink operated by the OTC Markets Group if one or more brokers choose to make a market for the Shares. To the extent the Shares are quoted on the OTC Pink, the company expects such market may provide significantly less liquidity than the NYSE American, and trading prices of the Shares may decline. However, there can be no assurances regarding any such initial quotation, the existence of a market or trading prices. Due to the risks and uncertainties resulting from the BIA proceedings, trading in the company's Shares during the pendency of the BIA proceedings poses substantial risks.

07:38 EDT Eros Media World files appeal with NYSE staff on delisting determination - Eros Media World has announced that it has duly filed an appeal with the New York Stock Exchange to review the determination made by the NYSE Regulation to commence proceedings to delist the Company's A ordinary shares and suspend trading immediately . The Company's request for a review of the Staff Determination by a committee of the Board of Directors of the NYSE is in accordance with Section 804.00 of the NYSE's Listed Company Manual. The company's request has been acknowledged by the NYSE last week in a letter, further confirming December 15 as scheduled date of review.

07:34 EDT Avrobio announces approval of Hunter syndrome CTA - Avrobio announced that the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, Research Ethics Committee, or REC, and Health Research Authority, or HRA, have approved the clinical trial application, or CTA, submitted by Avrobio's collaborators at the University of Manchester, U.K. for initiation of the Phase 1/2 clinical trial of investigational autologous hematopoietic stem cell, or HSC, gene therapy in infants diagnosed with neuronopathic mucopolysaccharidosis type II, or nMPS-II, or Hunter syndrome. This rare and seriously debilitating lysosomal disorder primarily affects young males. UoM's 24-month, non-randomized, open label study will enroll up to five children aged three months and 12 months diagnosed with nMPS-II to evaluate the safety and tolerability, pharmacodynamic and clinical efficacy of HSC gene therapy. The gene therapy, which Avrobio refers to as AVR-RD-05, is designed to transduce autologous HSCs ex vivo with a lentiviral vector encoding a brain-targeted iduronate-2-sulfatase enzyme, which is deficient in these patients. UoM expects to dose the first patient in the trial in 1H 2023. In these mouse models of Hunter syndrome, brain-targeted HSC gene therapy showed improvement across multiple metrics, including normalization of skeletal features such as the cheekbone dimensions, the width of the humerus and femur bones, correction of neurons in the brain and the preservation of higher brain functions including working memory.

07:33 EDT Nucor drops 5% to $129.40 after Q3 EPS guidance misses estimates

07:31 EDT Mind Medicine regains compliance with NASDAQ listing requirements - Mind Medicine announced that it has received a letter from The Nasdaq Stock Market advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. The Company has satisfied the terms for continued listing on the Nasdaq Capital Market by complying with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, and all other criteria for continued listing. Accordingly, Nasdaq has advised that the matter is now closed.

07:18 EDT Larimar Therapeutics announces $70M underwritten offering - Larimar Therapeutics announced the pricing of an underwritten offering of 22,225,000 shares of common stock. The shares are being sold at an offering price of $3.15 per share, which is equal to the closing price on Nasdaq for Larimar's common stock on September 13, 2022. The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $70.0 million. The offering is expected to close on or about September 16, 2022, subject to customary closing conditions. Larimar has granted the underwriters a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price, less underwriting discounts and commissions. Deerfield Management and other notable life science investors participated in the offering. Guggenheim Securities, LLC is acting as lead book-running manager for the offering and William Blair & Company, L.L.C. is also acting as a book-runner for the offering. LifeSci Capital LLC and JMP Securities, a Citizens Company, are acting as co-managers for the offering. Larimar intends to use the net proceeds from the offering to support the clinical development of CTI-1601, and for working capital and general corporate purposes, including research and development expenses.

07:16 EDT Sarepta prices $1B of convertible senior notes due 2027 - Sarepta Therapeutics announced the pricing of $980M aggregate principal amount of convertible senior unsecured notes that will mature on September 15, 2027, unless earlier redeemed, repurchased or converted. The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Sarepta has also granted the initial purchasers of the notes an option to purchase up to an additional $150M aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on September 16, 2022, subject to customary closing conditions. An entity affiliated with a member of Sarepta's Board of Directors has agreed to purchase $20M aggregate principal amount of the notes in a separate concurrent private placement under Section 4(a)(2) of the Act. The offering of the notes in the Rule 144A offering is not conditioned upon the closing of the concurrent private placement, but the concurrent private placement is conditioned upon the closing of the Rule 144A offering. Sarepta estimates that the net proceeds of the offerings will be approximately $979.4M after deducting the initial purchasers' discounts and commissions and estimated offering expenses payable by Sarepta. Sarepta intends to use $110.7M of the net proceeds from the offerings to pay the cost of the capped call transactions, and approximately $248.3M to repurchase approximately $150.6M in aggregate principal amount of its 1.50% Convertible Senior Notes due 2024, inclusive of any applicable premium and accrued interest. In addition, Sarepta intends to use approximately $585.5M of the net proceeds from the offerings to repay borrowings under, to pay accrued and unpaid interest and prepayment fees under, and terminate its credit agreement and the remaining net proceeds to fund general corporate purposes. Sarepta anticipates that, along with current cash and projected revenue, this offering is sufficient to fund operations to profitability.

07:12 EDT OraSure collaborates with Mars Petcare to better understand pet health - OraSure Technologies announced a new collaboration between Diversigen, a subsidiary of OraSure Technologies, and Mars Petcare, which will help researchers better understand pet health. As part of the MARS PETCARE BIOBANK project, Diversigen will sequence microbiome samples from cats and dogs of all breeds and breed makeups in efforts to improve pet care. "This collaboration will utilize Diversigen's specialized metagenomics service that uses curated databases to improve sample analysis," said Kathleen Weber, President of Molecular Solutions for OraSure Technologies. "Our team of expert scientists and bioinformaticians will help researchers involved in the project improve the understanding of canine and feline microbial community composition and function." Samples collected as part of the biobank study will be analyzed and Diversigen will sequence the DNA of the microorganisms in the sample.

07:10 EDT American Rebel signs LOI with Sierra E-Life, to enter E-Bike business - American Rebel announces signing a letter of intent, LOI, with Sierra E-Life, a full-service USA manufacturer of E-Bikes. "We are very excited to diversify our product offerings, thereby enhancing American Rebel as a lifestyle brand, by entering the futuristic, technology-savvy market of E-Bikes," said American Rebel CEO Andy Ross. "We think the E-Bike market is ready for the E-Bike with an attitude! American Rebel's grit, style and patriotic appeal will carry through to every product we design and put the American Rebel name on." American Rebel, in collaboration with Sierra E-Life, has designed three distinct E-Bike models: the Patriot 500, the Freedom 750 and the Rebel 1000. The Patriot 500, the Freedom 750 and the Rebel 1000 are projected to be Made in the USA with global components.

07:08 EDT American Rebel signs LOI with Deerfield, to enter E-Bike business - American Rebel announces signing a letter of intent, LOI, with Deerfield, Florida based Sierra E-Life, a full-service USA manufacturer of E-Bikes. "We are very excited to diversify our product offerings, thereby enhancing American Rebel as a lifestyle brand, by entering the futuristic, technology-savvy market of E-Bikes," said American Rebel CEO Andy Ross. "We think the E-Bike market is ready for the E-Bike with an attitude! American Rebel's grit, style and patriotic appeal will carry through to every product we design and put the American Rebel name on." American Rebel, in collaboration with Sierra E-Life, has designed three distinct E-Bike models: the Patriot 500, the Freedom 750 and the Rebel 1000. The Patriot 500, the Freedom 750 and the Rebel 1000 are projected to be Made in the USA with global components.

07:07 EDT Altimmune announces results from Phase 1b study of pemvidutide - Altimmune announced "positive" topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease. NAFLD. The trial was a randomized, double-blind, placebo-controlled study, with Dr. Stephen A. Harrison, Medical Director, Pinnacle Research, serving as the Principal Investigator. The primary efficacy endpoint was the percent reduction in liver fat content from baseline, and the key secondary efficacy endpoint was the % weight loss from baseline, both at 12 weeks of treatment. The trial was conducted without adjunctive diet and exercise interventions that are the standard for obesity trials. Ninety-four subjects were randomized and treated at 13 sites across the U.S. Mean BMI at baseline was approximately 36 kg/m2 and mean liver fat content, as measured by MRI-PDFF, was approximately 22%. Twenty-seven subjects had type 2 diabetes at baseline, and approximately 75% of study subjects were of Hispanic ethnicity. The trial met its primary endpoint in all pemvidutide treatment groups. At the 1.8 mg dos, pemvidutide achieved a mean reduction of liver fat content of 68.5%, with 94.4% of subjects achieving a 30% reduction in liver fat, 72.2% achieving a 50% reduction in liver fat, and 55.6% of subjects achieving normalization of liver fat, defined as liver fat fraction of 5% or less. In addition, mean serum alanine aminotransferase levels declined in all subjects, and in subjects with baseline serum ALT above 30 IU/L, levels declined more than 17 IU/L at all dose levels and 27.0 IU/L in the 2.4 mg dose cohort. The trial also met its key secondary endpoint in all pemvidutide treatment groups. Employing an efficacy estimand, mean weight losses of 4.9% in subjects without diabetes and 4.4% in subjects with diabetes were achieved at the 1.8 and 2.4 mg doses, respectively. Pemvidutide was reported to be generally well tolerated. Gastrointestinal events comprised the majority of the adverse events. Even without dose titration, the symptoms experienced by subjects were predominantly mild and transient in nature, consistent with known GLP-1 class effects. "We are pleased with the results of this trial, including the extent of liver fat and serum ALT reductions. Weight loss was within our target range, and good tolerability was observed without the need for dose titration. In addition, no clinically significant ALT elevations were observed," said Vipin Garg,, President and Chief Executive Officer of Altimmune. "With these positive results in hand, we look forward to reporting data from the 24-week NAFLD trial, as well as 24-week interim data from our MOMENTUM obesity trial."

07:05 EDT Akoustis receives development order for XBAW 5G mobile filter solution - Akoustis Technologies announced that it has received an order for the development of a new 5G mobile XBAW filter for a tier-1 RF module maker. Akoustis received a purchase order from this customer in December of 2021 for delivery of resonator models to be used in the design of the new 5G mobile filter, with first sample delivery expected in the second half of calendar 2022 and production-ready filters expected by the end of calendar 2023, in-line with Akoustis' planned capacity expansion. The customer is a tier-1 RF module maker that is leveraging Akoustis' leading XBAW filter technology to address a difficult coexistence frequency band in 5G mobile. Akoustis expects that this customer will develop additional 5G mobile filters upon the successful completion of this initial design.

07:05 EDT Ondas gets Canadian approval to sell 900 MHz ATCS platform - Ondas Holdings Ondas Networks and American Robotics , announced that Ondas Networks has received authorization from the Canadian government to sell its 900 MHz Advanced Train Control System platform. The ATCS platform, which had previously been introduced to the U.S. market, is now available for deployment throughout the Canadian rail system. The products will be sold and marketed by Siemens Mobility under their Airlink brand name to both Canadian freight and transit rail customers.

07:04 EDT Glory Star New Media launches CheerReal NFT application - Glory Star New Media Group Holdings announced that on September 9 it has officially launched CheerReal, a self-developed brand-new digital collection non-fungible tokens, or NFT, application, in both iOS and Android. Users can download CheerReal either from iOS or Android App Stores to get access to the digital arts on their mobile devices.

07:03 EDT Dow an Mura plan to construct new facility at Bohlen - Dow and Mura Technology announce the next step in their ongoing collaboration to help solve the global plastics waste issue and advance circularity. Mura plans to construct a new facility at Dow's Bohlen site in Germany - the latest in a series of planned facilities across the U.S. and Europe to rapidly scale advanced recycling of plastics - and the first expected to be based at a Dow site. This project is targeted for a final investment decision by the end of 2023. Mura's new Bohlen facility in Germany, which is expected to be operational by 2025, would deliver approximately 120 kilotons per annum, or KTA, of advanced recycling capacity at full run-rate. This and the other planned units expected to be constructed across Europe and the U.S. would collectively add as much as 600KTA of advanced recycling capacity by 2030 - and position Dow to become the largest consumer of circular feedstock for polyethylene production globally. Dow aims to take advantage of co-location benefits, which could significantly reduce the cost of scaling advance recycling facilities. In addition, co-location of Mura's facilities at Dow locations would be expected to reduce carbon emissions by minimizing transportation of the offtake and as gas output from the advanced recycling process can be converted back to plastics, thereby ensuring no by-products go to waste.

06:49 EDT Compass Minerals to receive $252M investment from Koch Minerals & Trading - Compass Minerals announced that Koch Minerals & Trading, a subsidiary of Koch Industries, has agreed to make a $252M investment in Compass Minerals through the purchase of Compass Minerals common stock to support phase-one development of its previously identified 2.4 mMT lithium carbonate equivalent Great Salt Lake resource and debt reduction. Approximately $200M of the proceeds from the investment are expected to be used to advance the first phase of the company's sustainable lithium development project. This figure represents approximately 75% of total phase-one funding needs, according to the company's FEL-1 level project cost estimates. Compass Minerals expects the project's annual commercial production capacity to ultimately be approximately 35 kMT LCE, with an initial phase-one capacity of approximately 11 kMT LCE coming online by 2025. As part of the agreement, the companies will also explore value creation opportunities across Compass Minerals' broader operational platform by leveraging the expansive capabilities of KII's many operating subsidiaries, including in the areas of supply and procurement of fuel and raw materials, freight and logistics synergies, and project engineering and development support. Compass Minerals expects to use the remaining $52M of proceeds from the KM&T investment, less transaction expenses, to reduce debt, representing a significant step toward aligning the company's capital structure with its corporate growth strategy. Under the terms of the investment agreement, KM&T has agreed to purchase 6,830,700 shares of Compass Minerals common stock at a price of $36.87 per share, resulting in proceeds to Compass Minerals of $252M. The issuance price represents a 6.2% discount to the closing price and an 8.0% discount to the 5-day volume weighted average price as of Sept. 13. After the transaction closes, KM&T will own approximately 17% of Compass Minerals' outstanding shares of common stock and will have the ability to appoint two additional members to the Compass Minerals board of directors. Perella Weinberg Partners LP acted as sole financial advisor to Compass Minerals in the transaction and Cleary Gottlieb Steen & Hamilton acted as the company's legal advisor. Jones Day acted as legal advisor for KM&T.

06:38 EDT Trimble acquires B2W Software, terms undisclosed - Trimble announced it has acquired privately-held B2W Software, a provider of estimating and operations solutions for the heavy civil construction industry. Financial terms were not disclosed. With the passage of the Infrastructure Investment and Jobs Act, or IIJA, and other infrastructure legislation across the globe, construction organizations are fast tracking the digitization of their processes and operations. As infrastructure projects become increasingly complex, data-driven insights and analytics will be imperative to improve productivity, increase efficiency and drive sustainability. B2W will be reported as part of the Buildings and Infrastructure segment.

06:35 EDT Centrus Energy secures new nuclear fuel sales contracts worth $320M - Centrus Energy announced that it has secured new nuclear fuel sales contracts and commitments with an estimated value of approximately $320M in the last 12 months -- including approximately $270M year-to-date. Most of Centrus' revenues come from multi-year contracts with major utilities, often signed years in advance. The new sales commitments cover deliveries from 2022 to 2030, with the revenue and cost of sales to be booked in the quarter and year of delivery.

06:30 EDT Johnson & Johnson announces $5B share repurchase program - Johnson & Johnson announced that the Board of Directors has authorized the repurchase of up to $5B of the company's common stock.

05:36 EDT EU court upholds antitrust ruling against Google, reduces fine to EUR 4.125B - The European Union's General Court on Wednesday upheld an antitrust ruling against Google's parent company Alphabet but reduced its fine to EUR 4.125B from EUR 4.34B. The court said it "largely confirms the Commission's decision that Google imposed unlawful restrictions on manufacturers of Android mobile devices and mobile network operators in order to consolidate the dominant position of its search engine." It added that "In order better to reflect the gravity and duration of the infringement, the General Court considers it appropriate however to impose a fine of EUR 4.125B on Google, its reasoning differing in certain respects from that of the Commission." Reference Link

05:19 EDT Melco Resorts & Entertainment submits application for Macau gaming concession - Melco Resorts & Entertainment announced that Melco Resorts Macau, a subsidiary of the company, submitted its detailed proposal in relation to the public tender for new gaming concessions launched by the Macau Government in July this year.

05:17 EDT IBM, Bharti Airtel announce collaboration - IBM and Bharti Airtel announced their intent to work together to deploy Airtel's edge computing platform in India, which will include 120 network data centers across 20 cities. Once deployed, the platform is designed to enable large enterprises across multiple industries including manufacturing and automotive to accelerate innovative solutions that deliver new value to their clients and operations.

05:10 EDT Las Vegas Sands, Sands China submit application new Macao gaming concession - Las Vegas Sands (LVS) and Sands China (SCHYY) announced the submission of the Sands China group's application for a new 10-year gaming concession in Macao. The company also announced that Dave Sun MinQi, who has served as Sands China's chief financial officer since 2017 and has been with the company since 2007, has been proposed to also act as the future managing director of Venetian Macau. Additionally, Grant Chum Kwan Lock, who serves as chief operating officer and a member of the Sands China's board of directors, is also taking on the role of executive vice president of Asia operations for Las Vegas Sands.